Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive condition caused by mutation(s) in the CNTNAP2 gene, encoding contactin-associated protein-like 2. It is characterized by normal development until the onset of intractable focal seizures at age 1-9. After the onset of seizures, language regression, intellectual disability, hyperactivity, and impulsive behaviors begin to occur. The majority of children eventually fulfill the criteria for autism spectrum disorder.
Features include always present findings: Bilateral tonic-clonic seizure, Strabismus, Focal impaired awareness seizure, and Intellectual disability and others; and very common findings: Seizure, EEG abnormality, Global developmental delay, and Delayed gross motor development and others. 84 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 26 | Bilateral tonic-clonic seizure, Poor speech, Dystonia |
CNTNAP2 encodes contactin associated protein 2 (1,331 aa). Required for gap junction formation (Probable). Required, with CNTNAP1, for radial and longitudinal organization of myelinated axons. Highest expression in Brain Frontal Cortex BA9 (26.0 TPM) and Brain Spinal cord cervical c-1 (23.2 TPM).
Cortical dysplasia-focal epilepsy syndrome is associated with mutations in the CNTNAP2 gene on chromosome 7.
CNTNAP2 is classified as a druggable target (Cell Surface, Druggable Genome, Fibrinogen, and Transcription Factor categories) with score 0.0.
Genetic testing for CNTNAP2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cortical dysplasia-focal epilepsy syndrome has been reported in the published literature.
Phenotype severity distribution: 9 always present features, 6 very common features, 14 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for cortical dysplasia-focal epilepsy syndrome.
2 publications have been identified in PubMed for cortical dysplasia-focal epilepsy syndrome. Research spans Diagnostic / Biomarker (50%) and Basic Science / Preclinical (50%).
Chalkiadaki K (2025). [PMID: 39758604](https://pubmed.ncbi.nlm.nih.gov/39758604/). *Biol Psychiatry Glob Open Sci*. [Basic Science / Preclinical]
Garcia-Uzquiano R (2024). [PMID: 38829689](https://pubmed.ncbi.nlm.nih.gov/38829689/). *Epilepsia Open*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 8:30 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Head and neck | 7 | Tented upper lip vermilion, Coarse facial features, Microcephaly |
Muscles | 6 | Low muscle tone (hypotonia), Generalized hypotonia, Delayed gross motor development |
Ears | 1 | Hearing loss (hearing impairment) |
Eyes | 1 | Strabismus |
Digestive system | 1 | Constipation |